172 related articles for article (PubMed ID: 27622033)
1. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
Anastasopoulou EA; Voutsas IF; Papamichail M; Baxevanis CN; Perez SA
Oncoimmunology; 2016 Jul; 5(7):e1178439. PubMed ID: 27622033
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
3. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract][Full Text] [Related]
4. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
[TBL] [Abstract][Full Text] [Related]
5. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
[TBL] [Abstract][Full Text] [Related]
7. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
9. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
[TBL] [Abstract][Full Text] [Related]
10. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
[TBL] [Abstract][Full Text] [Related]
11. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
[TBL] [Abstract][Full Text] [Related]
12. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
13. AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
[TBL] [Abstract][Full Text] [Related]
14. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
15. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
16. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
Schuhmacher J; Heidu S; Balchen T; Richardson JR; Schmeltz C; Sonne J; Schweiker J; Rammensee HG; Thor Straten P; Røder MA; Brasso K; Gouttefangeas C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33184050
[TBL] [Abstract][Full Text] [Related]
18. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
